Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer
Actuate Therapeutics, Inc.
Actuate Therapeutics Inc. (ACTU)
Market is closed
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.00 | 125,000 | $1,000,000.00 | 125,000 | 2024-08-14 | Filing | |
| $8.00 | 375,000 | $3,000,000.00 | 1,259,427 | 2024-08-14 | Filing | |
| $8.00 | 125,000 | $1,000,000.00 | 125,000 | 2024-08-14 | Filing | |
| $8.00 | 375,000 | $3,000,000.00 | 1,259,427 | 2024-08-14 | Filing | |
| $8.00 | 125,000 | $1,000,000.00 | 125,000 | 2024-08-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.00 | 2,324 | $18,592.00 | 131,248 | 2024-08-14 | Filing | |
| $8.00 | 17,361 | $138,888.00 | 980,433 | 2024-08-14 | Filing | |
| $8.00 | 5,314 | $42,512.00 | 300,143 | 2024-08-14 | Filing | |
| $8.00 | 2,324 | $18,592.00 | 131,248 | 2024-08-14 | Filing | |
| $8.00 | 17,361 | $138,888.00 | 980,433 | 2024-08-14 | Filing |
News See All
Billionaire Hedge Funds
